荷兰2013-2024年婴儿百日咳疫苗接种对1-2岁儿童的高有效性
本研究采用病例对照设计,纳入2013-2024年荷兰12-35月龄实验室确诊百日咳病例1156例及匹配对照4624例,评估婴儿百日咳疫苗完全接种的疫苗有效性(VE)。结果显示总体VE为98.2%(95%CI: 97.6-98.6),且随接种后时间延长而下降(p<0.001)。筛查法估计总体VE为96.4%(95%CI: 95.9-96.8),趋势一致,强调高婴儿疫苗接种率的重要性。
要点
- 婴儿百日咳疫苗完全接种对12-35月龄儿童总体VE达98.2%。
- VE随接种后时间延长而下降(p<0.001)。
- 筛查法估计VE略低(96.4%),但趋势一致。
核心结论
- 婴儿百日咳疫苗完全接种在36月龄内具有高有效性。
- 两种方法结果一致,强调高婴儿疫苗接种率的重要性。
研究设计与样本
- 病例对照研究,纳入2013-2024年荷兰12-35月龄实验室确诊百日咳病例1156例,每例按出生年月匹配4名对照,共4624名对照。
- 使用条件logistic回归(含年龄组和NIP时期交互项)估计OR,并与筛查法(以国家疫苗接种覆盖率的对数几率为偏移项)比较。
主要发现
- 病例中完全接种占27%、部分接种4%、未接种69%;对照中分别为89%、6%、5%。
- 病例对照法总体VE为98.2%(95%CI: 97.6-98.6)。
- VE随接种后时间延长而下降(p<0.001),NIP时期1较时期2下降更明显(p<0.001)。
- 筛查法总体VE为96.4%(95%CI: 95.9-96.8),趋势相似。
关键数值与推荐
- 完全接种婴儿百日咳疫苗对12-35月龄儿童总体VE为98.2%(95%CI: 97.6-98.6)。
- 筛查法估计总体VE为96.4%(95%CI: 95.9-96.8)。
- VE随接种后时间延长而下降(p<0.001)。
临床怎么用
- 应维持并提高婴儿百日咳疫苗的高接种率以保护1-2岁儿童。
- 需关注接种后时间延长导致的VE下降,适时评估加强免疫策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: With still high circulation of pertussis and risk for severe disease in young children, insight into vaccine effectiveness (VE) of infant pertussis vaccination is important. In the Netherlands, NIP period 1 corresponds to the period during which the DT3aP-IPV-Hib-HBV vaccine and the 3 + 1 dose schedule were used, and NIP period 2 to the period during which the DT5aP-IPV-Hib-HBV vaccine was used, maternal Tdap vaccination was implemented, and both the 3 + 1 and 2 + 1 dose schedules were used. We estimated the VE of full infant vaccination against pertussis. METHODS: We conducted a case-control study including all laboratory-confirmed pertussis cases aged 12-35 months, notified between 2013 and 2024, each matched to four controls by year and month of birth. Conditional logistic regression including age group and NIP period as interaction terms was used to estimate stratum-specific odds ratios (ORs) with 95% confidence intervals (CIs). We compared these estimates to those obtained by the screening method, applying logistic regression with the log-odds of the national vaccination coverage in the corresponding birth cohorts of cases as an offset. VE was calculated as (1-OR)*100 for both methods. RESULTS: We included 1156 cases and 4624 controls. Among cases, 27% were fully vaccinated, 4% partly vaccinated and 69% unvaccinated; among controls these percentages were 89%, 6% and 5% respectively. Overall VE of the case-control study was 98.2% (95% CI: 97.6-98.6). VE decreased with increasing time since vaccination (p < 0.001) and this was slightly more pronounced for NIP period 1 compared to period 2 (p < 0.001). Estimates using the screening method were slightly lower, with overall VE being 96.4% (95% CI: 95.9-96.8), but similar trends were observed. CONCLUSION: Full infant pertussis vaccination is highly effective up to 36 months of age. These findings, consistent across both methods, emphasize importance of high infant pertussis vaccination uptake.
引用
- van Meijeren DL, van Roon AM, de Gier B, et al. High effectiveness of infant vaccination against pertussis in 1- and 2-year-olds, the Netherlands, 2013-2024. Vaccine. 2026. PMID: 42526173. doi:10.1016/j.vaccine.2026.128978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。